Private biotech 2004- the numbers

Article Abstract:

An analysis of the financial performance of the privately held biotech sector in 2004 in the US and Europe is presented as around 85% of all healthcare and healthcare-related biotech companies are privately owned. The area of focus for examining during the research includes employment, research and development, raising finance, generating revenue till becoming a public company.

Europe, Sales & consumption, Industry sales and revenue

---

Where the money is

Article Abstract:

The US capital markets' role in making the US biotech tech industry as one of the worlds largest in both market value and product sales is examined. The future of the US capital market, its competitors around the world and fate of the global biotech industry are discussed.

Forecasts, trends, outlooks, Contracts & orders received, Contracts & orders let, Forecasts and trends, Contracts, Capital market, Capital markets, Market trend/market analysis, Contract agreement

---

Similar abstracts:

• Abstracts: The beginning of the end game. Only for the brave. Living on the edge
• Abstracts: Shift toward early-stage deals favors bioteochs. Public biotech 2006- the numbers
• Abstracts: Power to the people. A fare job. Retail therapy
• Abstracts: Cross-decking, other moves permit more missions with same ships. Adm. Nathman says perhaps just 40 to 50 LCSs required
• Abstracts: VAT update. VAT update: Carousel fraud- the end of the road

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.